Urology
Volume 79, Issue 1 , Pages 102-108 , January 2012

Diabetes Treatment and Progression of Benign Prostatic Hyperplasia in Community-dwelling Black and White Men

  • Aruna V. Sarma

      Affiliations

    • Department of Urology, University of Michigan Medical School, Ann Arbor, Michigan
    • Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan
    • Corresponding Author InformationReprint requests: Aruna V. Sarma, Ph.D., Department of Urology, University of Michigan Medical School, 2800 Plymouth Road, Building 520, No. 3171, Ann Arbor, MI 48109-2800
    • ,
  • Jennifer L. St. Sauver

      Affiliations

    • Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota
    • ,
  • John M. Hollingsworth

      Affiliations

    • Department of Urology, University of Michigan Medical School, Ann Arbor, Michigan
    • ,
  • Debra J. Jacobson

      Affiliations

    • Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota
    • ,
  • Michaela E. McGree

      Affiliations

    • Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota
    • ,
  • Rodney L. Dunn

      Affiliations

    • Department of Urology, University of Michigan Medical School, Ann Arbor, Michigan
    • ,
  • Michael M. Lieber

      Affiliations

    • Department of Urology, Mayo Clinic, Rochester, Minnesota
    • ,
  • Steven J. Jacobsen

      Affiliations

    • Southern California Permanente Medical Group, Pasadena, California
    • ,
  • Urologic Diseases in America Project

Received 5 May 2011 ,Accepted 31 August 2011.

References 

  1. Wei JT , Calhoun E , Jacobsen SJ . Urologic diseases in America project: benign prostatic hyperplasia . J Urol . 2008;179:S75–S80
  2. Sarma AV , Burke JP , Jacobson DJ , et al.  Associations between diabetes and clinical markers of benign prostatic hyperplasia among community-dwelling black and white men . Diabetes Care . 2008;31:476–482
  3. Chute CG , Panser LA , Girman CJ , et al.  The prevalence of prostatism: a population-based survey of urinary symptoms . J Urol . 1993;150:85–89
  4. Wei JT , Schottenfeld D , Cooper K , et al.  The natural history of lower urinary tract symptoms in black American men: relationships with aging, prostate size, flow rate and bothersomeness . J Urol . 2001;165:1521–1525
  5. Barry MJ , Fowler FJ , O'Leary MP , et al.  The American Urological Association symptom index for benign prostatic hyperplasia: the Measurement Committee of the American Urological Association . J Urol . 1992;148:1549–1557 1564
  6. Jacobsen SJ , Jacobson DJ , Girman CJ , et al.  Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status . J Urol . 1999;162:1301–1306
  7. Michel MC , Mehlburger L , Schumacher H , et al.  Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia . J Urol . 2000;163:1725–1729
  8. Brown JS , Seeley DG , Fong J , et al.  Urinary incontinence in older women: who is at risk? (Study of Osteoporotic Fractures Research Group) . Obstet Gynecol . 1996;87:715–721
  9. Hammarsten J , Hogstedt B . Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia . Blood Press . 1999;8:29–36
  10. Hammarsten J , Hogstedt B . Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia . Eur Urol . 2001;39:151–158
  11. Hammarsten J , Hogstedt B , Holthuis N , et al.  Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia . Prostate Cancer Prostatic Dis . 1998;1:157–162
  12. Meigs JB , Mohr B , Barry MJ , et al.  Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men . J Clin Epidemiol . 2001;54:935–944
  13. Joseph MA , Harlow SD , Wei JT , et al.  Risk factors for lower urinary tract symptoms in a population-based sample of African-American men . Am J Epidemiol . 2003;157:906–914
  14. Sandfeldt L , Hahn RG . Cardiovascular risk factors correlate with prostate size in men with bladder outlet obstruction . BJU Int . 2003;92:64–68
  15. Kupelian V , McVary KT , Kaplan SA , et al.  Association of lower urinary tract symptoms and the metabolic syndrome: results from the Boston Area Community Health Survey . J Urol . 2009;182:616–625
  16. Boon TA , Van Venrooij GE , Eckhardt MD . Effect of diabetes mellitus on lower urinary tract symptoms and dysfunction in patients with benign prostatic hyperplasia . Curr Urol Rep . 2001;2:297–301
  17. Glynn RJ , Campion EW , Bouchard GR , et al.  The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study . Am J Epidemiol . 1985;121:78–90
  18. Burke JP , Jacobson DJ , McGree M , et al.  Diabetes and benign prostatic hyperplasia progression in Olmsted County, Minnesota . Urology . 2006;67:22–25
  19. Brown JS , Wessells H , Chancellor MB , et al.  Urologic complications of diabetes . Diabetes Care . 2005;28:177–185
  20. Roberts RO , Lieber MM , Jacobsen DJ , et al.  Limitations of using outcomes in the placebo arm of a clinical trial of benign prostatic hyperplasia to quantify those in the community . Mayo Clin Proc . 2005;80:759–764
  21. Guess HA , Jacobsen SJ , Girman CJ , et al.  The role of community-based longitudinal studies in evaluating treatment effects (Example: benign prostatic hyperplasia) . Med Care . 1995;33:AS26–AS35
  22. Matthiesen TB , Rittig S , Nørgaard JP , et al.  Nocturnal polyuria and natriuresis in male patients with nocturia and lower urinary tract symptoms . J Urol . 1996;156:1292–1299
  23. Yoshimura K , Terada N , Matsui Y , et al.  Prevalence of and risk factors for nocturia: analysis of a health screening program . Int J Urol . 2004;11:282–287
  24. Chasens ER , Umlauf MQ , Pillion DJ , et al.  Nocturnal polyuria in type 2 diabetes: a symptom of obstructive sleep apnea . Diabetes Educ . 2002;28:424–434
  25. Hsing AW , Chua S , Gao YT , et al.  Prostate cancer risk and serum levels of insulin and leptin: a population-based study . J Natl Cancer Inst . 2001;93:783–789
  26. Guess HA . Benign prostatic hyperplasia and prostate cancer . Epidemiol Rev . 2001;23:152–158
  27. Menéndez V , Cofán F , Talbot-Wright R , et al.  Urodynamic evaluation in simultaneous insulin-dependent diabetes mellitus and end stage renal disease . J Urol . 1996;155:2001–2004
  28. Sarma AV , Jaffe CA , Schottenfeld D , et al.  Insulin-like growth factor-1, insulin-like growth factor binding protein-3, and body mass index: clinical correlates of prostate volume among black men . Urology . 2002;59:362–367
  29. Platz EA , Pollak MN , Rimm EB , et al.  Racial variation in insulin-like growth factor-1 and binding protein-3 concentrations in middle-aged men . Cancer Epidemiol Biomarkers Prev . 1999;8:1107–1110

 Funding Support: This research was supported by the Urologic Diseases in America Project.

PII: S0090-4295(11)02343-0

doi: 10.1016/j.urology.2011.08.065

Urology
Volume 79, Issue 1 , Pages 102-108 , January 2012

Article Tools